FMP
Protagenic Therapeutics, Inc.
PTIX
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
0.388 USD
-0.0304 (-7.84%)
Historical Prices
From:
To:
About
ceo
Dr. Garo H. Armen Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.protagenic.comexchange
NASDAQ
Description
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
CIK
0001022899
ISIN
US74365N2027
CUSIP
74365N103
Address
149 Fifth Avenue
Phone
212 994 8200
Country
US
Employee
1
IPO Date
Apr 27, 2021
Financial Statement
Earnings
PTIX Financial Summary
CIK
0001022899
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
74365N103
ISIN
US74365N2027
Country
US
Price
0.39
Beta
0.35
Volume Avg.
5.41M
Market Cap
2.92M
Shares
-
52-Week
0.179-1.87
DCF
0.38
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.34
P/B
-
Website
https://www.protagenic.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest PTIX News
Alex Lavoie
Jan 27, 2025
Comparative Analysis of Biotechnology Stocks: Protagenic The...
Protagenic Therapeutics, Inc. (NASDAQ:PTIX) is a biotechnology company focused on developing therapies for stress-related disorders. Currently, PTIX is trading at $0.445, with a target price of $0.296, indicating a potential downside of approximately -33.39%. This significant gap between the current and target prices suggests a pessimistic outlook from investment analysts, leading to its exclusion from coverage. In comparison, Cyteir Therapeutics, Inc. (CYT) presents a more promising investment...
Seeking Alpha
Apr 1, 2024
Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call T...
Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript
Accesswire
Mar 25, 2024
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earni...
Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY 2024. The Company plans to hold its earnings call, open to the public, at 4:30 pm ET on Monday, April 1st, to discuss the results of ...
Accesswire
Oct 13, 2023
Protagenic Therapeutics Announces Date of Annual Shareholder...
NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced its FY 2022 annual shareholder meeting will be held Wednesday, December 13, 2023, at 10:00 am EST, for shareholders of record as of this coming Monday, October 16th. Those who would like to attend the meeting virtually may do so by going to the website www.virtualshareholdermeeting.com/...
Accesswire
Apr 26, 2022
Protagenic Therapeutics to Present at the B. Riley Securitie...
NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic disorders, today announced will be presenting at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference tomorrow, April 27, 2022.
Pulse2
Aug 19, 2021
Protagenic Therapeutics Shares Increase Over 10% Pre-Market:...
The shares of Protagenic Therapeutics Inc (NASDAQ: PTIX) increased by over 10% pre-market. This is why it happened.
Benzinga
Jul 26, 2021
Protagenic Therapeutics To Start Clinical Trials For Depress...
Upon reviewing Protagenic Therapeutics Inc's (NASDAQ: PTIX) Investigational New Drug (IND) application for its lead compound, PT00114, the FDA has currently rejected the Company's IND. The application sought approval to start a Phase 1/2a basket study designed to test PT00114 in healthy volunteers and patients with PTSD, anxiety, and depression.
GlobeNewsWire
Jul 6, 2021
Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fa...
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that it will host a key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addiction on Tuesday, July 13 at 10:00AM ET.
